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Abstract
Sudden cardiac death or sudden cardiac arrest (SCA) is defined as natural death that occurs
within an hour of the onset of acute symptoms or during sleep due to a primary cardiac cause.
Most cases of SCA are attributable to coronary artery disease, with occult cardiomyopathy or
inheritable arrhythmic syndromes accounting for a minority of SCA. Diagnosing the cause of
SCA has potential implications for the patient and the family, and demands a comprehensive
approach. This review summarizes the potential causes of SCA and outlines a systematic
diagnostic approach to the SCA survivor. (Cardiol J 2011; 18, 2: 210–216)
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Introduction
Sudden death is defined as natural (non-trau-
matic) death that occurs within an hour of the on-
set of acute symptoms or during sleep [1]. Although
sudden non-traumatic deaths are frequently attri-
buted to cardiac disease, autopsy studies in unselect-
ed subjects suggest that about one third of sudden
deaths have non-cardiac causes (eg: intracranial
bleed, pulmonary embolism, acute asthma) [2]. The
sub-division of sudden death based on underlying
cardiac causes is defined as sudden cardiac death
or sudden cardiac arrest (SCA). There may or may
not be a pre-existing diagnosis of heart disease, but
the time and mode of death are unexpected.
The reported incidence rates of SCA are varia-
ble. This variability is related to the study popula-
tion and the inherent vagaries of classifying the
mode and time of death, particularly in the absence
of post-mortem studies. The incidence of SCA in-
creases from less than 10 per 100,000 person-years
in young healthy individuals (age < 35 years) to
over 50 per 10,000 person-years in patients with
structural heart disease, and the incidence is greater
in males compared to females [3].
Coronary artery disease (CAD) and the asso-
ciated complications account for the majority of SCA
[4], and arrhythmic syndromes are often regarded
the prima facie cause of SCA in the absence of sig-
nificant CAD. Avoiding the pitfalls of misdiagnosis,
the potential implications for the patient and the
family demands a comprehensive and systematic
approach for the identification of reversible or at-
tributable causes in the SCA survivor. This review
will outline a diagnostic approach to the SCA sur-
vivor.
Diagnostic strategy
A systematic approach to the evaluation of sur-
vivors of SCA should identify potentially correct-
able or reversible causes, underlying structural
heart disease and the less common inherited ar-
rhythmia syndromes. An explanation for SCA can
be identified in the majority of survivors from rou-
tine diagnostic investigations (including coronary
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angiography and cardiac imaging), as SCA occurs
most commonly in the context of structural heart
disease.
The remaining patients with unexplained car-
diac arrest based on initial diagnostic evaluation
should undergo further systematic and progressive
clinical testing, including cardiac imaging and pro-
vocative pharmacological testing. A cause can be
identified in more than half of the patients with ap-
parently unexplained cardiac arrest with this stra-
tegy of systematic diagnostic testing (Figs. 1, 2) [5].
The minority of patients without an identifiable
cause despite this strategy of rigorous testing are
diagnosed with idiopathic ventricular fibrillation.
Routine assessment/investigations
Clinical history
The value of a detailed clinical history cannot
be overstated. Details of the circumstances preced-
ing the cardiac arrest are crucial and witnesses may
need to be interviewed. Cardiac arrest associated
with exertion is suggestive of CAD [6, 7], but is also
a well-recognized trigger in the less common inheri-
ted arrhythmic syndromes (eg: long QT syndrome
[LQTS] and catecholaminergic polymorphic ventri-
cular tachycardia [CPVT]) [8] and some cardiomyo-
Figure 1. Progressive diagnostic evaluation of the sud-
den cardiac arrest survivor; *non-invasive assessment
of coronary artery abnormalities by cardiac computed
tomography or magnetic resonance imaging.
Figure 2. Causes of sudden cardiac death (idiopathic ventricular fibrillation is diagnosed in the absence of an identi-
fiable cause from these investigations); RV — right ventricular; VT — ventricular tachycardia.
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pathies. Febrile illness should raise suspicion of
myocarditis, particularly if associated with features
of heart failure. Ventricular arrhythmias may also
be precipitated by febrile illness in patients with
Brugada syndrome [9].
The family history is vital in the diagnostic
evaluation of possible heritable arrhythmic syn-
dromes. A simple inquiry restricted to premature
deaths in first-degree relatives risks missing all but
the most conspicuous patterns of phenotypic trans-
mission of heritable conditions. A detailed inquiry
should ideally include a three-generation pedigree
of not only premature deaths, but also individuals
with syncope, neuromuscular disorders, learning
difficulties, unexplained single vehicle accidents,
sudden infant deaths and even sensorineural deaf-
ness (Jervell Lange-Nielsen syndrome [10]). Multi-
disciplinary team support from clinical geneticists
and genetic counselors is invaluable in the diagno-
sis of potential heritable arrhythmic syndromes,
particularly if genetic assessment is considered.
The association between drugs and fatal ven-
tricular arrhythmias is well documented. The use
of QT prolonging drugs in susceptible individu-
als, or pharmacokinetic and pharmacodynamic
drug interactions can increase the risk of ventri-
cular arrhythmia. A detailed drug history should
include the use of all drugs, whether prescribed,
over the counter or recreational/illicit and sup-
plements. A history suggestive of drug use should
prompt toxicology screening in addition to rou-
tine biochemistry.
Electrocardiogram (ECG),
telemetry and signal-averaged ECG
Serial ECGs are mandatory in SCA survivors
for the diagnosis of acute myocardial ischemia/infar-
ction, conduction abnormalities, and depolarization
and repolarization abnormalities. Additional right-
-sided, lateral and posterior leads may be helpful if
acute myocardial ischemia/infarction is suspected
from adjacent standard leads or elevated markers of
myocardial damage. Continuous ECG telemetry
(> 72 h) can identify recurrent myocardial ischemia
and sustained or non-sustained arrhythmias, and
should be routine during hospitalization.
Bradyarrhythmias account for about 1 in 5 of
all SCA based on recordings from ambulatory ECGs
[11]. Myocarditis, infiltrative cardiomyopathies and
neuromuscular disorders may be associated with
significant conduction abnormalities. Paroxysmal
atrio-ventricular block as a result of disease in the
His-Purkinje system is characterized by an abrupt
change from 1:1 conduction to complete heart block,
which can lead to prolonged ventricular asystole or
torsades de pointes [12]. A preceding history of
syncope is common and normal 1:1 conduction on
resting ECG does not exclude this condition. Diag-
nosis requires clinical vigilance, continuous ECG
telemetry and serial ECGs. A prolonged PR inter-
val (> 210 ms) may also identify patients with Bru-
gada syndrome with SCN5A mutation [13].
Areas of myocardial necrosis, scar or ischemia
result in inhomogenous ventricular depolarization
and present a substrate for reentrant ventricular
arrhythmias. This may manifest as additional notch-
ing (R’ or S’) or fragmentation of the QRS complex-
es on surface ECG. Quantitatively defined fragmen-
tation of the QRS complexes based on specific scor-
ing algorithms is associated with increased
mortality [14] and arrhythmic events in patients
with implantable defibrillators [15]. Areas of slow
conduction due to myocardial scarring can also be
detected as late potentials at the terminal portion
of the QRS on signal-averaged ECG (SAECG). The
latter is a useful tool to assess for a potential latent
myopathic process such as arrhythmogenic right
ventricular cardiomyopathy (ARVC), sarcoidosis, or
myocarditis. A filtered QRS duration longer than
114 ms is the most sensitive parameter on SAECG
at predicting the risk of sudden cardiac death [16].
Other parameters that are considered abnormal are
low-amplitude signal duration ≥ 38 ms and a root
mean square voltage of the terminal 40 ms of the
QRS complex less than 20 µV at 40-Hz filter set-
tings. These parameters in the SAECG have recent-
ly been included as minor criteria in the 2010 Task
Force Criteria for the diagnosis of ARVC [17].
Sudden cardiac death related to abnormalities
of ventricular repolarization (eg: long QT, Brugada
and early repolarization syndromes) is well reco-
gnized. The T wave morphology and QT interval
should be measured and adjusted for heart rate.
Linear regression functions have been recommend-
ed for the adjustment of the QT interval for heart
rate [18], but the Bazett formula (measured QT di-
vided by the square root of the RR interval) [19]
remains widely used. The method of QT adjustment
for heart rate should be specified. Transient repo-
larization changes and QT prolongation related to
acute myocardial infarction [20], anoxic brain injury
[21] and induced hypothermia [22] is common. Con-
versely, repolarization changes may be absent on the
resting ECGs in patients with congenital repolariza-
tion abnormalities. In this regard, serial ECGs and
provocation testing are helpful (see below).
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Coronary angiography
Coronary angiography is indicated in most car-
diac arrest survivors. Conventional invasive coro-
nary angiography is preferred in patients with clini-
cal suspicion of CAD or evidence of myocardial
infarction (eg: elevated cardiac enzymes or abnor-
malities on cardiac imaging). However, coronary
angiography by computed tomography now offers
a non-invasive alternative for the assessment of
coronary artery anatomy, particularly in patients
with low clinical suspicion of CAD (eg: young pa-
tients with no cardiovascular risk factors and nor-
mal left ventricular dysfunction).
Coronary spasm and consequent myocardial
ischemia may precipitate ventricular arrhythmias
[23]. Minor, non-obstructive coronary stenoses are
typical in patients with coronary spasm, and a com-
pletely normal coronary angiogram is unusual [24].
Provocation testing with ergonovine or acetylcho-
line is generally limited to selected cases in view
of the small risk of precipitating potentially fatal
myocardial infarction and arrhythmias. Magnetic
resonance imaging (MRI) detection of late gadoli-
nium enhancement may be useful for detecting oc-
cult infarction that warrants consideration of a care-
ful search for coronary spasm.
Cardiac imaging
Cardiac imaging in the SCA survivor aims to
(i) assess cardiac morphology and function, (ii) cha-
racterize the cardiomyopathy, and (iii) stratify risk
of adverse clinical outcomes and guide therapeutic
interventions. This process often requires different
imaging modalities. Echocardiography and cardiac
MRI represent the dominant imaging modalities in
clinical practice.
Echocardiography in the presence of good
acoustic windows is a reliable imaging modality for
the assessment of cardiac size/function and valvu-
lar abnormalities, but may be inadequate for the
phenotypic characterization of the cardiomyopathy.
In contrast to echocardiography, cardiac MRI has
unrestricted range of tomographic planes and high
spatial resolution, allowing excellent delineation of
endocardial and epicardial borders and more repro-
ducible data. As a result, cardiac MRI is now con-
sidered the ‘gold standard’ for the assessment of
cardiac anatomy, chamber volumes and ventricular
function. Angiography by cardiac MRI can also be
used to assess coronary artery anomalies.
Cardiac MRI can identify and quantify myocar-
dial scar/fibrosis by using specific inversion reco-
very gradient echo sequences at least 10 min after
the intravenous injection of gadolinium-chelated
contrast agents (late gadolinium enhancement). The
pattern/distribution of late gadolinium enhancement
can distinguish ischemic (typically sub-endocardial
or transmural) from non-ischemic cardiomyopathy
(mid-myocardial or epicardial). In addition, T2-
-weighted imaging, which highlights unbound water
in the myocardium, can identify areas of edema as-
sociated with inflammation (such as myocarditis and
sarcoidosis) or acute ischemia [25]. Myocardial fi-
brosis detected by late gadolinium enhancement on
cardiac MRI is associated with increased frequen-
cy of ventricular arrhythmias in patients with idio-
pathic dilated cardiomyopathy and hypertrophic
cardiomyopathy [26–28].
T1-weighted images (with and without fat sup-
pression) on cardiac MRI have been used to identi-
fy areas of fatty infiltration in the right ventricular
wall, but this parameter has poor sensitivity and
specificity for the diagnosis of ARVC [29]. In con-
trast, global or regional right ventricular wall mo-
tion abnormalities are specific (in experienced
hands) and recognized as a criterion for the diagno-
sis of ARVC [17].
Exercise test
Exercise testing is used routinely for the as-
sessment of CAD and often overlooked following
coronary angiography. Exercise testing should be
performed in patients with unexplained cardiac ar-
rest to unmask phenotypic evidence of inherited
arrhythmic syndrome or exercise-induced arrhyth-
mia such as polymorphic ventricular tachycardia in
CPVT, sustained ventricular tachycardia in ARVC
and QT prolongation/T wave changes in LQTS.
Type 1 LQTS (LQT1) is associated with marked
prolongation of QTc interval at peak exercise [30,
31]. Exercise testing may also induce ECG chang-
es in Brugada syndrome [32].
Exercise testing should be accompanied by
continuous ECG monitoring with measurement of the
ST segment, QT interval and blood pressure measure-
ments. Intravenous beta-blocking agents and resus-
citation equipment should be available in the event of
exercise-induced ventricular arrhythmia. The failure
of blood pressure to increase or a drop in blood pres-
sure in response to upright exercise testing can
identify patients with hypertrophic cardiomyopathy
at increased risk of sudden death [33].
Discretionary investigations
Pharmacological challenge
The diagnostic features of arrhythmic syn-
dromes are often intermittent, subtle or absent on
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the resting ECG. Challenging or ‘stressing’ the
dominant ion channel abnormality or the specific
mechanism of the arrhythmia with pharmacologic
agents can unmask the latent ECG abnormalities.
Epinephrine infusion has been used in the clini-
cal evaluation of LQTS. Two infusion protocols
have been developed — the epinephrine bolus fol-
lowed by infusion [34] and the graded epinephrine
infusion [35]. The latter is better tolerated and may
be associated with lower incidence of false-positive
responses. The graded epinephrine infusion is com-
menced at 0.05 µg//kg/min, doubling every 5 min
to 0.2 µg/kg/min, and the QT interval is measured
at each increment and at 5 and 10 min following the
infusion. An absolute increase in QT interval of
at least 30 ms at low dose epinephrine infusion
(£ 0.1 µg/kg/min) is considered abnormal and pro-
vides a presumptive diagnosis of LQT1 [36]. Of
note, the result of epinephrine challenge should not
be inferred from exercise testing and vice versa, as
epinephrine infusion results in greater QT short-
ening for a given increase in heart rate compared
to exercise testing [37]. Epinephrine infusion can
also been used to unmask catecholaminergic poly-
morphic ventricular tachycardia [38].
Epinephrine infusion should be stopped in the
event of raised systolic blood pressure over 200 mm
Hg, non-sustained ventricular tachycardia or poly-
morphic ventricular tachycardia, frequent (> 10)
premature ventricular contractions/minute, T-wave
alternans, or patient intolerance. Appropriate resus-
citation equipment (and intravenous metoprolol)
should be available despite the reported safety of
epinephrine challenge.
Provocative pharmacological testing with intra-
venous class IC sodium channel blockers (ajmaline
1 mg/kg; flecainide 2 mg/kg, maximum 150 mg or
procainamide 15 mg/kg, maximum 1 g depending
on availability) is used to unmask or amplify the ST
changes in patients with Brugada syndrome. The
development of typical type 1 Brugada ECG pattern
(≥ 2-mm J-point elevation and coved type ST-T seg-
ment elevation in leads V1 and V2) is considered
positive [39]. Monitoring should be continued until
normalization of the ECG. Placing the precordial
leads at higher intercostal space increases the sen-
sitivity of detecting typical Brugada ECG pattern
compared to conventional 12-lead ECG (Fig. 3) [40].
Isoproterenol may be used to suppress ventricular
arrhythmias in patients with Brugada syndrome [41].
Electrophysiological study (EPS)
Electrophysiological testing has been used to
identify patients with a substrate for ventricular
arrhythmias and at high risk of SCA, though it has
a limited role in general and is not routinely per-
formed. In the presence of structural heart disease,
inducible sustained monomorphic ventricular tachy-
cardia with up to 3 ventricular extrastimuli at 2 drive
cycle lengths is considered abnormal and associat-
ed with high risk of sudden cardiac death [42]. How-
ever, a low risk of SCA cannot be inferred by the
absence of inducible ventricular tachycardia. EPS
also provides little prognostic data in patients with
non-ischemic cardiomyopathy [43]. Indeed, EPS has
limited value in guiding therapeutic interventions
in SCA survivors, as implantable cardioverter-
-defibrillator is indicated in all survivors in the ab-
sence of specific contraindications [44].
Similarly, the failure to induce ventricular ta-
chycardia does not obviate the need for implantable
cardioverter-defibrillator in patients with ARVC and
prior cardiac arrest [45]. However, EPS in conjunc-
tion with voltage mapping can corroborate evidence
of scar from imaging studies to support the diagno-
sis in ARVC [46] and may identify patients at high
risk of recurrent arrhythmia [47]. EPS and ablation
is indicated in patients with SCA and ventricular
pre-excitation.
Other considerations
In rare cases, endomyocardial biopsy guided by
the results of other diagnostic modalities may be
Figure 3. Positioning of high precordial leads (hV1 to
hV6) for procainamide challenge to increase sensitivity
of detecting Brugada pattern.
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helpful in the diagnosis of myocarditis, ARVC or
cardiac masses.
The discovery of mutations in genes associat-
ed with specific cardiac ion channels or cardiomyo-
pathies has spurred interest in genetic testing to
diagnose, risk stratify and guide the management
of SCA survivors and their families. However, there
are major caveats to the use of genetic testing, not
least is the poor negative predictive value (a nega-
tive test does not exclude the presence of an inher-
itable arrhythmic syndrome) and the low yield (and
unfavorable cost-effectiveness) of routine indiscri-
minate genetic testing without a defined clinical phe-
notype [48]. Hence, genetic testing can only be re-
commended as an adjunct to phenotypic testing in
SCA survivors. The result of the genetic testing
(guided by the clinical phenotype) can be used to
identify other family members who have inherited
that particular mutation and at risk of developing the
disease (cascade screening) [49]. This is the prima-
ry purpose of conducting targeted genetic testing.
Conclusions
An underlying structural heart disease can be
uncovered in the majority of SCA survivors from
routine diagnostic testing. For the minority of pa-
tients without evident structural heart disease,
a systematic use of invasive and non-invasive clini-
cal testing, in particular provocative drug testing
and advanced cardiac imaging can uncover a diag-
nosis and direct genetic testing to identify geneti-
cally-mediated arrhythmia syndromes.
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